Publicaciones en colaboración con investigadores/as de Hospital POVISA (9)

2022

  1. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group

    Cancer Treatment and Research Communications, Vol. 33

2021

  1. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

2020

  1. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: A pairwise meta-analysis

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-13

2018

  1. Real world data of nivolumab for previously treated non-small cell lung cancer patients: A Galician lung cancer group clinical experience

    Translational Lung Cancer Research, Vol. 7, Núm. 3, pp. 404-415

2016

  1. EGFR testing and clinical management of advanced NSCLC: A galician lung cancer group study (GGCP 048-10)

    Cancer Management and Research, Vol. 8, pp. 11-20

2014

  1. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): A Galician Lung Cancer Group (GGCP) study

    Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 3, pp. 451-457

  2. Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: Review of patient profile

    Anti-Cancer Drugs, Vol. 25, Núm. 4, pp. 368-374

2012

  1. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

    Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 10, pp. 1389-1396

2007

  1. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: A lung cancer Galician group phase II study

    Cancer Chemotherapy and Pharmacology, Vol. 60, Núm. 5, pp. 725-732